<DOC>
	<DOC>NCT02676154</DOC>
	<brief_summary>This study will be investigating the effects of fesoterodine on autonomic dysreflexia (AD) in patients with spinal cord injuries (SCI). The goal of the study is to examine the effect of increasing daily use of fesoterodine on episodes of high blood pressure triggered by urinary bladder contractions.</brief_summary>
	<brief_title>Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)</brief_title>
	<detailed_description>This is a Phase 2, open-label exploratory study investigating the efficacy of fesoterodine for treatment of adult patients with spinal cord injuries (SCI) with autonomic dysreflexia (AD) triggered by neurogenic detrusor overactivity (NDO).</detailed_description>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Autonomic Dysreflexia</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>The inclusion criteria include, but are not limited to, the following: Male or female, 18 55 years of age Chronic traumatic SCI at or above T6 spinal segment and &gt;1 year post injury Documented presence of AD and NDO during UDS Hand function sufficient to perform CIC Willing and able to comply with all clinic visits and studyrelated procedures Able to understand and complete studyrelated questionnaires Pregnant or Breastfeeding women Sexually active males with female partners must agree to use effective contraception during the period of the trial and for at least 28 days after completion of treatment Must Provide Informed Consent The exclusion criteria include, but are not limited to, the following: Presence of severe acute medical issue that in the investigator's judgement would adversely affect the patient's participation in the study A hypersensitivity to tolterodine (available as Detrol, Detrol LA), soya, peanuts, or lactose Recent treatment with intravesical OnabotulinumtoxinA (within 9 months of the baseline visit) Recent treatment with other anticholinergics medications (within 3 weeks of the baseline visit) Use of any medication or treatment that in the opinion of the investigator indicates that it is not in the best interest of the patient to participate in this study Patient is a member of the investigational team or his /her immediate family</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Episodic Hypertension</keyword>
	<keyword>Spinal Cord Injury</keyword>
	<keyword>Traumatic Spinal Cord Injury</keyword>
	<keyword>Blood Pressure</keyword>
	<keyword>Fesoterodine</keyword>
	<keyword>Neurogenic Detrusor Overactivity</keyword>
	<keyword>Autonomic Dysreflexia</keyword>
	<keyword>Urodynamic Studies</keyword>
	<keyword>24 Hour Ambulatory Blood Pressure Monitoring</keyword>
</DOC>